Veltuzumab
| Veltuzumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Veltuzumab is a monoclonal antibody designed for the treatment of cancer and autoimmune diseases. It specifically targets the CD20 molecule found on the surface of B cells, which are a type of white blood cell involved in the immune response. By binding to CD20, veltuzumab initiates the destruction of B cells, which is beneficial in conditions where B cells are malignant or are contributing to pathogenic autoimmunity.
Mechanism of Action
Veltuzumab functions by binding to the CD20 antigen on B cells. This binding initiates cellular cytotoxicity and leads to the depletion of B cells. The reduction in B cell population helps in reducing the pathological activity in autoimmune diseases and contributes to the destruction of malignant B cells in cancers such as non-Hodgkin lymphoma.
Clinical Uses
Veltuzumab has been investigated in several clinical trials for its efficacy and safety in treating conditions like non-Hodgkin lymphoma and chronic lymphocytic leukemia. It has also been studied for potential use in treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.
Development and Approval
The development of veltuzumab has involved various phases of clinical trials to assess its therapeutic potential and safety profile. As of the last update, veltuzumab has not yet received approval from major regulatory bodies like the U.S. Food and Drug Administration (FDA) for any indication, and it remains under investigation.
Side Effects
Like other monoclonal antibodies targeting B cells, veltuzumab can cause side effects, including infusion reactions, infections due to immunosuppression, and potential long-term effects on the immune system. Clinical trials continue to monitor these aspects to better understand the risk profile of veltuzumab.
Future Directions
Research continues to explore the full potential of veltuzumab in various therapeutic areas. Future studies are expected to define its role in treatment protocols, possibly in combination with other therapeutic agents.
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD